PureTech Health (GB:PRTC) has released an update.
PureTech Health, a clinical-stage biotherapeutics company, announced a transfer of shares by non-executive director John LaMattina to support Boston College. The transaction involved 52,640 shares and was conducted outside of a trading venue. This move highlights PureTech’s commitment to impactful collaborations and philanthropic efforts.
For further insights into GB:PRTC stock, check out TipRanks’ Stock Analysis page.
